Document Detail


Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides.
MedLine Citation:
PMID:  20935558     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
OBJECTIVES: In chronic HIV-1 infection, the efficacy of a cellular immune response may decline if the virus evolves into variants not recognized by host immune response. The aim of this study was to explore HIV-1 immune escape mutations imposed by therapeutic immunization by investigating sequence variations that might contribute to relapse of viremia in an immunized, HIV-1-infected cohort.
DESIGN: We have previously immunized HIV-1-infected individuals on antiretroviral therapy (ART) with a mixture of four short peptides (Vacc-4x) corresponding to p24. Long postimmunization periods without ART allowed longitudinal sequence studies of regions corresponding to Vacc-4x.
METHODS: Regions of gag p24 including the locations of the Vacc-4x peptides, were sequenced before start of ART, and after postimmunization ART stop (n = 27). Rates and locations of amino acid substitutions were then related to peptide-specific T-cell responses and known epitopes presented by Vacc-4x.
RESULTS: The overall rate of amino acid substitutions was low during 35 months (median) of postimmunization viremia, with similar rates of substitution within the regions corresponding to Vacc-4x peptides and other p24 regions despite durable Vacc-4x-specific T-cell responses. Postimmunization amino acid substitutions within Vacc-4x regions were detected in only six patients, and only two of them had measurable T-cell responses against the relevant peptide.
CONCLUSIONS: The results suggested low prevalence of evolutionary selection of p24 despite new and long-lasting Vacc-4x-specific T-cell responses. The conserved Vacc-4x sequences might therefore be particularly suited for therapeutic immunization. Generally, studies of longitudinal sequence variations after immunization might be valuable when assessing immune escape in HIV vaccine trials.
Authors:
Anne-Marte B Kran; Tom Oystein Jonassen; Maja A Sommerfelt; Gunilla Løvgården; Birger Sørensen; Dag Kvale
Related Documents :
16481078 - Primary and memory t cell responses induced by hepatitis c virus multiepitope long pept...
8903318 - F(c)gammari-targeted fusion proteins result in efficient presentation by human monocyte...
20080728 - A self-assembling peptide acting as an immune adjuvant.
14760758 - Purification of heat shock protein 70-associated tumor peptides and their antitumor imm...
1781888 - Basic fibroblast growth factor is a beta-rich protein.
22553998 - Enhancing and limiting endothelin-1 signaling with a cell-penetrating peptide mimicking...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  AIDS (London, England)     Volume:  24     ISSN:  1473-5571     ISO Abbreviation:  AIDS     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710219     Medline TA:  AIDS     Country:  England    
Other Details:
Languages:  eng     Pagination:  2609-18     Citation Subset:  IM; X    
Affiliation:
Department of Infectious Diseases, Oslo University Hospital, Ullevål, Norway. a.m.b.kran@medisin.uio.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatic safety and tolerability in the maraviroc clinical development program.
Next Document:  Cardiorespiratory instability before and after implementing an integrated monitoring system.